Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

TCT 2017: Frailty provides prognostic value for TAVR patients—but better risk scores are needed

DENVER — Measuring frailty could lead to more accurate predictions of outcomes following transcatheter aortic valve replacement (TAVR) than a validated risk algorithm, according to research presented Oct. 30 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Thumbnail

Heart surgeries performed later in the day linked to better outcomes

The time of day a patient receives open-heart surgery could impact their postoperative outcomes, according to a new study in The Lancet.

First Patient Treated in Landmark Transcatheter Mitral Valve Replacement (TMVR) Pivotal Trial

Medtronic plc (NYSE:MDT) today announced the first patient implant in the APOLLO Trial — the pivotal trial designed to evaluate the Intrepid(TM) TMVR system following receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).

Thumbnail

Transcatheter ASD closure improves tricuspid regurgitation, heart failure symptoms

Transcatheter closure of the atrial septal defect (ASD) resulted in significant reductions in tricuspid regurgitation (TR) and improvements in right ventricular dimensions, according to a new study in JACC: Cardiovascular Interventions.

Thumbnail

Environmental, genetic factors linked to increased risk of CHD in infants of diabetic mothers

A previously unknown gene-environment interaction between maternal diabetes and transcriptional regulator Notch1 raises the risk of congenital heart disease (CHD) in children, a paper published in the Journal of Clinical Investigation: Insight states.

CytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve Survival

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the largest endocarditis valve replacement study using CytoSorb published to date entitled, "Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass – a case series".

Thumbnail

More good news on TAVR

Just-released studies shine more positive light on TAVR in terms of durability five years out and long-term survival, with women outpacing men by about 15 percent.

Thumbnail

Patients for Life: Preparing for the Adult CHD Surge

Are enough resources available to treat the growing population of adults with congenital heart disease?   

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.